European Metals Holdings (ASX:EMH) Cinovec Project is strategically located in the heart of the growing European EV ecosystem in the northwest of the Czech Republic. Cinovec is a large historic lithium resource, with a clean pathway to underground development. EMH’s 51 per cent JV partner is the national utility CEZ a subsidiary of CEZ Group, which is owned 70 per cent by the Czech Government.
Copyright 2023 – Finance News Network
17 Aug 2022 - CARETEQ Limited (ASX:CTQ) Executive Chairman Mark Simari discusses the company's recent agreement with drug management platform StrongRoom AI and the transition from paper-based to digital record keeping within the aged care and assistive living sector.
06 May 2020 - Acorn Capital Investment Fund Ltd. (ASX: ACQ) Head of Research and Portfolio Manager for the Consumer Discretionary, Consumer Staples and Information Technology sectors, Robert Bruce talks about the listed investment company, the fund’s composition and outlook for the next 6 months and longer term.
23 Feb 2024 - Discover Sunshine Metals' strategic focus on Queensland's prolific gold and base metal districts, unveiling promising exploration ventures and recent resource upgrades.
20 May 2021 - Complii FinTech Solutions Limited (ASX:CF1) Executive Chairman Craig Mason talks about how the company's digital platform provides an electronic centralised framework to manage AFSL-centric (Stockbroker/Financial Planner/Adviser) workflows for compliance, capital raising and operational efficiencies.
23 Apr 2021 - Capral Limited (ASX:CAA) Managing Director Tony Dragicevich talks about the company's strong FY20 results despite COVID, its product mix, operating environment and outlook.
02 Sep 2019 - Lithium Consolidated Limited (ASX:LI3) CEO, Shanthar Pathmanathan talks about the company's capital raising and focus on hard rock lithium and sale of its US lithium brine asset to Argosy Minerals.
15 Jul 2020 - Recce Pharmaceuticals Limited (ASX:RCE) Executive Director James Graham provides an update on positive data against a range of persistent bacteria using the company's synthetic antibiotic RECCE 327, commencement of Phase I human clinical trial in 2H20 and key priorities.
